Results 41 to 50 of about 132,020 (160)

Vaccines for epidemic infections and the role of CEPI

open access: yesHuman Vaccines & Immunotherapeutics, 2017
The author reviews the foundation of the Coalition for Epidemic Preparedness and Innovations and the choices it has made for funding of vaccine development against epidemic diseases.
Stanley A. Plotkin
doaj   +1 more source

Epidemics and Reforms: Experience of Saudi Arabia

open access: yesМеждународная аналитика, 2020
Saudi Arabia is one of the key countries in the Middle East and the Arab-Muslim world. The processes developing in this country, determined by both internal and external factors, are directly related to the development of the surrounding geopolitical ...
G. G. Kosach
doaj   +1 more source

Number of clusters for each single-sized library of 3-mers, 6-mers, 9-mers.

open access: yes, 2017
Number of clusters for each single-sized library of 3-mers, 6-mers, 9-mers.
Fábio Lima Custódio (3639205)   +3 more
core   +1 more source

MERS-CoV antibodies in humans, Africa, 2013–2014 [PDF]

open access: yes, 2016
Dromedaries in Africa and elsewhere carry the Middle East respiratory syndrome coronavirus (MERS-CoV). To search for evidence of autochthonous MERS-CoV infection in humans, we tested archived serum from livestock handlers in Kenya for MERS-CoV antibodies.
Njeru, Ian   +27 more
core   +2 more sources

Immune-profiling of innate and adaptive immunity following three vaccinations of the MERS vaccine candidate MVA-MERS-S [PDF]

open access: yes, 2022
Middle East Respiratory Syndrome (MERS) is a respiratory disease caused by MERS coronavirus (MERS-CoV). In follow-up to a phase 1 trial, we performed a longitudinal analysis of immune responses following immunization with the Modified Vaccinia virus ...
Weskamm, Leonie M.   +6 more
core   +1 more source

New MERS-CoV Vaccine

open access: yes, 2023
The present invention relates to a mutant receptor-binding domain (MERS-mRBD) of MERS-CoV (middle east respiratory syndrome coronavirus) or a fragment thereof and a mutant spike protein (MERS-mSpike) of MERS-CoV or a fragment thereof.
Vásquez García, C.   +3 more
core  

MERS-CoV‒Specific T-Cell Responses in Camels after Single MVA-MERS-S Vaccination

open access: yes, 2023
We developed an ELISPOT assay for evaluating Middle East respiratory syndrome coronavirus (MERS-CoV)‒specific T-cell responses in dromedary camels. After single modified vaccinia virus Ankara-MERS-S vaccination, seropositive camels showed increased ...
Vanessa Herder   +9 more
core   +1 more source

A Comparative Study of Clinical Presentation and Risk Factors for Adverse Outcome in Patients Hospitalised with Acute Respiratory Disease Due to MERS Coronavirus or Other Causes. [PDF]

open access: yesPLoS ONE, 2016
Middle East Respiratory syndrome (MERS) first emerged in Saudi Arabia in 2012 and remains a global health concern. The objective of this study was to compare the clinical features and risk factors for adverse outcome in patients with RT-PCR confirmed ...
Musa A Garbati   +8 more
doaj   +1 more source

MERS-CoV infection fails to activate the stress response pathway.

open access: yes, 2016
(A) Immune fluorescence images of mock-treated an MERS-CoV infected Vero cells. Cells were infected with an MOI of 1 and fixed using 3% paraformaldehyde in PBS at 10h or 24h post infection.
Isabel Sola (218107)   +10 more
core   +1 more source

MERS-CoV [PDF]

open access: yes, 2019
Middle East respiratory syndrome coronavirus (MERS-CoV) is an emerging zoonotic coronavirus. First identified in 2012, MERS-CoV has caused over 2460 infections and a fatality rate of about 35% in humans.
Du, Lanying, Li, Fang
core   +1 more source

Home - About - Disclaimer - Privacy